Semaglutide's Impact on Chronic Kidney Disease Progression in Type 2 Diabetes Patients Evaluated in New RCT

Patients with Type 2 Diabetes (T2D) face a significantly elevated risk of developing and progressing Chronic Kidney Disease (CKD), often leading to end-stage renal disease and increased mortality. Current standard-of-care treatments primarily focus on glycemic control and blood pressure management, but a substantial unmet need remains for therapies that directly slow kidney disease progression. GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and renal benefits beyond glycemic control in various populations, making them a promising candidate for targeted kidney protection in this vulnerable group.

This randomized, placebo-controlled clinical trial is enrolling participants diagnosed with Type 2 Diabetes and Chronic Kidney Disease. Participants are randomly assigned to receive either semaglutide or a placebo. The study medicine is administered via a pen injector, with participants performing a once-weekly subcutaneous injection into a skin fold. The trial's primary objective is to assess semaglutide's ability to slow the growth and worsening of CKD. The total study duration for each participant is anticipated to be between 3 to 5 years, with the trial concluding once sufficient data is collected to demonstrate clear results.